Stockreport

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Res...

ImmunityBio, Inc.  (IBRX) 
PDF High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolledUpdated data intended to be submitted as [Read more]